Where Insmed Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 Wall Street analysts have provided ratings for Insmed (NASDAQ:INSM), with 3 being bullish and 4 somewhat bullish. The average price target is $45.57, representing an implied upside from the current price of $24.82. This target has increased by 11.83% from the previous target of $40.75. Analyst ratings are important as they can influence investor expectations and stock prices.
November 20, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
7 analysts have a positive outlook on Insmed with an average price target of $45.57, indicating a potential upside from the current price of $24.82. The target has been raised by 11.83% from the previous $40.75.
The unanimous positive ratings from analysts, combined with a significant increase in the average price target, suggest a strong bullish sentiment for Insmed. This could lead to increased investor confidence and a potential short-term rise in the stock price, especially considering the substantial implied upside.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100